Altimmune to Announce Third Quarter 2020 Financial Results on November 10
Altimmune management will host a conference call for investors beginning at
Conference Call Details
| Date: | |
| Time: | |
| Domestic: | 877-300-8521 |
| International: | 412-317-6026 |
| Conference ID: | 10149733 |
| Webcast: | http://public.viavid.com/index.php?id=142319 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
| Investor Contacts: | ||
| Chief Financial Officer | ||
| Phone: 240-654-1450 | 617-430-7577 | |
| wbrown@altimmune.com | arr@lifesciadvisors.com | |
| Media Contacts: | ||
| Phone: 212-687-8080 | ||
| altimmune-svc@sardverb.com |
Source: Altimmune, Inc.
